Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.70 |
| ▸ | ATM | Q13315 | 1/20 | 0.70 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.53 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11727679 | 0.92 | — | — | |
| SCHEMBL4251673 | 0.92 | ATM (0.80) | MAPTATMADRA2AADRA2BADRA2C | |
| SCHEMBL11250545 | 0.92 | ATM (0.80) | MAPTATMADRA2AADRA2BADRA2C | |
| SCHEMBL3971687 | 0.85 | ATM (0.95) | MAPTATMADRA2AADRA2BADRA2C | |
| SCHEMBL10477 | 0.82 | ATM (1.00) | MAPTATMADRA2AADRA2BADRA2C | |
| SCHEMBL7571918 | 0.82 | — | — | |
| SCHEMBL4381896 | 0.82 | ATM (1.00) | MAPTATMADRA2AADRA2BADRA2C | |
| SCHEMBL4382059 | 0.82 | ATM (1.00) | MAPTATMADRA2AADRA2BADRA2C | |
| SCHEMBL22994928 | 0.81 | MAPT (0.64) | MAPTATMADRA2AADRA2BADRA2C | |
| SCHEMBL14357428 | 0.81 | MAPT (0.64) | MAPTATMADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5874573-A | Compounds with chelation affinity and selectivity for first transition series elements: use in medical therapy | CONCAT, INC. (US) | 1999-02-23 | — | — | US | claimed |
| US-20050112066-A1 | Complexes of cyclic polyaza chelators with cations of alkaline earth metals for enhanced biological activity | CONCAT LP, A CALIFORNIA LIMITED PARTNERSHIP (US) | 2005-05-26 | — | — | US | disclosed |
| EP-1382332-A1 | Method for inhibiting bacterial or fungal growth using a polyamine derivative as complexing agent | Chelator LLC (US) | 2004-01-21 | — | — | EP | disclosed |
| US-6583182-B1 | Atomic numbers 21-30 are components of enzymes required for nucleic acid replication; substituted polyaza compounds inhibit cell replication by decreaseing bioavailability of iron or copper | CHELATOR LLC | 2003-06-24 | — | — | US | disclosed |
| US-6469162-B1 | SUCH COMPOUNDS INHIBIT MAMMALIAN, BACTERIAL, AND FUNGAL CELL REPLICATION AND ARE USEFUL IN THE TREATMENT OF NEOPLASIA, INFECTION, INFLAMMATION, IMMUNE REPONSE, AND IN TERMINATION OF PREGNANCY | CONCAT, LTD. | 2002-10-22 | — | — | US | disclosed |
| US-6387891-B2 | COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS AND THEIR USE IN COSMETICS AND PERSONAL CARE PRODUCTS, INHIBITION OF METALLOENZYMES, AND INHIBITION OF REPERFUSION INJURY | CONCAT, LTD. | 2002-05-14 | — | — | US | disclosed |
| US-20010041170-A1 | Compounds with chelation affinity and selectivity for first transition series elements and their use in cosmetics and personal care products, inhibition of metalloenzymes, and inhibition of reperfusion injury | CHELATOR LLC | 2001-11-15 | — | — | US | disclosed |
| US-6264966-B1 | DEODORANTS; THERAPY FOR ORAL DISEASES | CONCAT, LTD. | 2001-07-24 | — | — | US | disclosed |
| US-6165996-A | Compounds with chelation affinity selectivity for first transition series elements: use in medical therapy and diagnosis | CONCAT, INC. (US) | 2000-12-26 | — | — | US | disclosed |
| EP-0955044-A2 | Method of inhibiting bacterial or fungal growth using a complexing agent | CONCAT LTD. (US) | 1999-11-10 | — | — | EP | disclosed |
| EP-0841951-A2 | COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS, AND THEIR USE IN MEDICAL THERAPY AND DIAGNOSIS | CONCAT LTD. (US) | 1998-05-20 | — | — | EP | disclosed |
| WO-1997001360-A2 | COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS AND THEIR USE IN MEDICAL THERAPY AND DIAGNOSIS | CONCAT, LTD. (US) | 1997-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041170-A1 | Compounds with chelation affinity and selectivity for first transition series elements and their use in cosmetics and personal care products, inhibition of metalloenzymes, and inhibition of reperfusion injury | MPO, LPO, SOD1 | MAPT 3867/4885ATM 3772/4885ADRA2A 4061/4885 |
| US-20050112066-A1 | Complexes of cyclic polyaza chelators with cations of alkaline earth metals for enhanced biological activity | SLC39A14, CHIA, CA2 | MAPT 3731/4885ATM 4174/4885ADRA2A 1628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.